[{"orgOrder":0,"company":"Young Pharmaceuticals","sponsor":"Lactobio A\/S","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Partnership","leadProduct":"LB356R","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Young Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Young Pharmaceuticals \/ Lactobio A\/S","highestDevelopmentStatusID":"15","companyTruncated":"Young Pharmaceuticals \/ Lactobio A\/S"}]

Find Clinical Drug Pipeline Developments & Deals by Young Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : The exclusive distribution agreement includes North America and will only be available through dispensing medical offices which include the LB356R fermented lysate of Lactiplantibacillus plantarum (former Lactobacillus plantarum) with the special functio...

                          Product Name : BAK

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          March 24, 2022

                          Lead Product(s) : LB356R

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Lactobio A/S

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank